The Acute Myeloid Leukemia Channel is supported with funding from BMS (Silver), and through an educational grant from Jazz Pharmaceuticals.
The Myelodysplastic Syndromes Channel is supported with funding from Geron (Silver).
VJHemOnc is an independent medical education platform. Supporters, including channel supporters, have no influence over the production of content. The levels of sponsorship listed are reflective of the amount of funding given to support the channel.
EHA 2022 | CD47 antibodies for the treatment of AML and MDS: where is the field moving?
Naval Daver, MD, University of Texas MD Anderson Cancer Center, Houston, TX, shares some insights into the promise of CD47 antibodies for the treatment of acute myeloid leukemia (AML) and myelodysplastic syndromes (MDS), including magrolimab, TTI-622, and lemzoparlimab. Dr Daver also highlights an upcoming trial which will investigate the safety and efficacy of lemzoparlimab combined with azacitidine or azacitidine and venetoclax in AML and MDS respectively (NCT04912063). This interview took place at the European Hematology Association (EHA) Congress 2022 held in Vienna, Austria.
